Dr. Yardley on the APHINITY Trial for HER2-Positive Breast Cancer

Denise Yardley, MD
Published: Monday, Jun 19, 2017



Denise Yardley, MD, senior investigator at the Sarah Cannon Research Institute, discusses the APHINITY trial investigating pertuzumab (Perjeta) for patients with adjuvant HER2-positive breast cancer.

The design of the APHINITY trial was either an anthracycline-based regimen for node-positive patients, chemotherapy with a trastuzumab (Herceptin)-based regimen for node-negative patients, or pertuzumab in combination with trastuzumab, explains Yardley.

Overall, this study has shown positive results of pertuzumab in the adjuvant setting for patients with HER2-positive breast cancer, states Yardley.
 
SELECTED
LANGUAGE


Denise Yardley, MD, senior investigator at the Sarah Cannon Research Institute, discusses the APHINITY trial investigating pertuzumab (Perjeta) for patients with adjuvant HER2-positive breast cancer.

The design of the APHINITY trial was either an anthracycline-based regimen for node-positive patients, chemotherapy with a trastuzumab (Herceptin)-based regimen for node-negative patients, or pertuzumab in combination with trastuzumab, explains Yardley.

Overall, this study has shown positive results of pertuzumab in the adjuvant setting for patients with HER2-positive breast cancer, states Yardley.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Community Practice Connections™: Evolving Applications for PARP Inhibitors in Ovarian Cancer: Building on a Solid FoundationAug 15, 20191.5
Publication Bottom Border
Border Publication
x